Today, though, the company is in the news again with a voluntary recall over the auto-injector devices.
Pfizer Canada has released a recall for two types of their emergency anti-allergy medication.
It says EpiPens distributed between January and March of past year and EpiPen Juniors from November 2015 to February 2016 were affected.
The drugmaker, Mylan, announced it is recalling more than 81,000 epipen devices in the United States and other continents.
Narvaez said the non-profit group started getting calls from patients and families after the recall was expanded to include the U.S.
UPI reported that the recalled EpiPen (0.3 mg) and EpiPen Jr.
The products can be replaced at no charge by calling 1-877-650-3494.
The notice issued Friday by Mylan N.V. expands upon warnings made earlier this month after two reports of the device failing. After Mylan bought the product in 2007 the drug company raised prices nearly 600 percent over the course of the next decade.
This, of course, could have significant health consequences for patients who are amid a life-threatening allergic reaction.
According to the recall announcement on Mylan's website, the risk of the defect is low, but the company is acting "out of an abundance of caution" to keep any defective pens out of circulation.
The company says that in total, more than 100,000 products that could be affected were distributed in Canada.